Novartis: PASSAGE Study

What is the PASSAGE Study?

The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with Fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of Fingolimod under conditions of routine medical practice.

Study Investigators: Dr. Teresa DeAngelis and Dr. Richard Blanck
ClinicalTrials.gov Identifier: NCT01442194
Link for more information: https://clinicaltrials.gov/ct2/show/NCT01442194?term=novartis+passage&rank=1